These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 27746107

  • 1. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK.
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract] [Full Text] [Related]

  • 2. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 3. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D, Hein R, Biedermann T, Kohlmeyer J.
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract] [Full Text] [Related]

  • 4. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D.
    Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
    [Abstract] [Full Text] [Related]

  • 5. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y.
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [Abstract] [Full Text] [Related]

  • 6. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B.
    Clin Cancer Res; 2016 Jun 15; 22(12):2908-18. PubMed ID: 26787752
    [Abstract] [Full Text] [Related]

  • 7. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R, Otsuka A, Kaku Y, Honda T, Kabashima K.
    Eur J Dermatol; 2018 Feb 01; 28(1):84-85. PubMed ID: 29400292
    [No Abstract] [Full Text] [Related]

  • 8. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M.
    Cancer Immunol Res; 2016 Sep 02; 4(9):744-54. PubMed ID: 27466265
    [Abstract] [Full Text] [Related]

  • 9. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
    Li M, Basu A, Bennette C, Veenstra D, Garrison LP.
    Value Health; 2019 Jul 02; 22(7):777-784. PubMed ID: 31277824
    [Abstract] [Full Text] [Related]

  • 10. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C, Reddy BY, Dellavalle RP, Sundararajan S.
    BMJ; 2017 Nov 30; 359():j5174. PubMed ID: 29191943
    [No Abstract] [Full Text] [Related]

  • 11. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
    Majenka P, Hoffmann M, Rötzer I, Dimitrakopoulou-Strauss A, Koschny R, Longerich T, Enk A, Hassel JC.
    Eur J Cancer; 2019 Jan 30; 106():220-224. PubMed ID: 30528806
    [No Abstract] [Full Text] [Related]

  • 12. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM, Robert C, Richtig E, Miller WH, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.
    Eur J Cancer; 2017 Nov 30; 86():115-124. PubMed ID: 28987768
    [Abstract] [Full Text] [Related]

  • 13. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 14. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, Pawelec G, Garbe C, Weide B.
    Clin Cancer Res; 2016 Oct 01; 22(19):4848-4858. PubMed ID: 27169993
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A, Jansky GL, Bauer JW, Koelblinger P.
    Melanoma Res; 2017 Oct 01; 27(5):524-525. PubMed ID: 28858175
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab.
    Schmid RK, Harker-Murray A, Niemczyk K, Robbins JR.
    Pract Radiat Oncol; 2018 Oct 01; 8(3):174-178. PubMed ID: 29122555
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.